14 Jun 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide obtains patent protection for FG001 in Australia

Press release

November 30, 2020

Copenhagen, Denmark, 30 November 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that the Company has successfully secured patent protection for its lead clinical asset FG001 in Australia. The protection is granted by the Australian Commissioner of Patents. The patent number is 2015317444 and will remain valid until September 2035.

FG001 is designed to allow surgeons to clearly delignate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology and is currently used in a phase I/II clinical trial in guiding surgery of high grade glioma.

The Australian Commissioner of Patents has granted and registered FluoGuide’s patent application for its lead asset FG001. The patent (no. 2015317444) with title “uPAR targeting peptide for use in peroperative optical imaging of invasive cancer” will remain valid until September 2035. The patent has previously been issued in the USA and Europe and with this patent, FluoGuide continues to expand it’s intellectual property portfolio for its lead asset.